Functional coexpression of Interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed-Sternberg cells: Involvement of IL-7 in tumor cell growth and microenvironmental interactions of Hodgkin's lymphoma

International Journal of Cancer

Volumn 125, Issue 5, 2009, Pages 1092-1101

  Cattaruzza, Lara ^a   Gloghini, Annunziata ^b   Olivo, Karin ^a   Di Francia, Raffaele ^c   Lorenzon, Debora ^a   De Filippi, Rosaria ^c,d   Carbone, Antonino ^b   Colombatti, Alfonso ^a,e   Pinto, Antonio ^c   Aldinucci, Donatella ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF UDINE   (Italy)

Author keywords

Cytokine receptors; Cytokines; Hodgkin lymphoma; Interleukin 7; Tumor microenvironment

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR; NEUTRALIZING ANTIBODY;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; CYTOKINE PRODUCTION; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE PROLIFERATION; MICROENVIRONMENT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REED STERNBERG CELL; REGULATORY T LYMPHOCYTE;

APOPTOSIS; AUTOCRINE COMMUNICATION; BLOTTING, WESTERN; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLASTS; FLOW CYTOMETRY; HODGKIN DISEASE; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-7; LYMPH NODES; PARACRINE COMMUNICATION; RECEPTORS, INTERLEUKIN-7; REED-STERNBERG CELLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STROMAL CELLS; T-LYMPHOCYTES, REGULATORY;

EID: 67650087810     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24389     Document Type: Article

References (66)

1. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002;99:4283-97.
2. Maggio E, van den Berg A, Diepstra A, Kluiver J, Visser L, Poppema S. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol 2002;13:52-6.
3. Chiu A, Xu W, He B, Dillon SR, Gross JA, Sievers E, Qiao X, Santini P, Hyjek E, Lee JW, Cesarman E, Chadburn A, et al. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood 2007;109:729-39.
4. Aldinucci D, Lorenzon D, Cattaruzza L, Pinto A, Gloghini A, Carbone A, Colombatti A. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer 2008;122:769-76.
5. Renné C, Minner S, Küppers R, Hansmann ML, Bräuninger A. Autocrine NGFbeta/TRKA signalling is an important survival factor for Hodgkin lymphoma derived cell lines. Leuk Res 2008;32:163-7.
6. Scheeren FA, Diehl SA, Smit LA, Beaumont T, Naspetti M, Bende RJ, Blom B, Karube K, Ohshima K, van Noesel CJ, Spits H. IL-21 is expressed in Hodgkin lymphoma and activates STAT5; evidence that activated STAT5 is required for Hodgkin lymphomagenesis. Blood 2008;111:4706-15.
7. Re D, Thomas RK, Behringer K, Diehl V. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood 2005;105:4553-60.
8. Ma Y, Visser L, Roelofsen H, de Vries M, Diepstra A, van Imhoff G, van der Wal T, Luinge M, Alvarez-Llamas G, Vos H, Poppema S, Vonk R, et al. Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood 2008;111:2339-46.
9. Gruss HJ, Pinto A, Duyster J, Poppema S, Herrmann F. Hodgkin's disease: a tumor with disturbed immunological pathways. Immunol Today 1997;18:156-63.
10. Jundt F, Anagnostopoulos I, Bommert K, Emmerich F, Müller G, Foss HD, Royer HD, Stein H, Dörken B. Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Blood 1999;94:2065-71.
11. Ohshima K, Sugihara M, Suzumiya J, Haraoka S, Kanda M, Shimazaki K, Katoh K, Kumagawa M, Kikuchi M. Basic fibroblast growth factor and fibrosis in Hodgkin's disease. Pathol Res Pract 1999;195: 149-55.
12. Teruya-Feldstein J, Jaffe ES, Burd PR, Kingma DW, Setsuda JE, Tosato G. Differential chemokine expression in tissues involved by Hodgkin's disease: direct correlation of eotaxin expression and tissue eosinophilia. Blood 1999;93:2463-70.
13. Rochester CL, Ackerman SJ, Zheng T, Elias JA. Eosinophil-fibroblast interactions. Granule major basic protein interacts with. IL-1 and transforming growth factor-beta in the stimulation of lung fibroblast. IL-6-type cytokine production. J Immunol 1996;156: 4449-56.
14. Aldinucci D, Lorenzon D, Olivo K, Rapanà B, Gattei V. Interactions between tissue fibroblasts in lymph nodes and Hodgkin/Reed-Sternberg cells. Leuk Lymphoma 2004;45:1731-9.
15. Brown RE, Shah NR, Lobel JS, George BA, Gaylord H, Simonich WL. Interleukin-6-associated laboratory parameters and immunohistochemistry in symptomatic stage A and B nodular sclerosing Hodgkin's disease in children. Ann Clin Lab Sci 1997;27:26-33.
16. Kurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J, Talpaz M. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res 1993;53:2118-22.
17. Gorschlüter M, Bohlen H, Hasenclever D, Diehl V, Tesch H. Serum cytokine levels correlate with clinical parameters in Hodgkin's disease. Ann Oncol 1995;6:477-82.
18. Tecchio C, Nadali G, Scapini P, Bonetto C, Visco C, Tamassia N, Vassilakopoulos TP, Pangalis GA, Calzetti F, Nardelli B, Roschke V, Gottardi M, et al. High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma. Br J Haematol 2007;137:553-9.
19. Oki Y, Georgakis GV, Migone TS, Kwak LW, Younes A. Prognostic significance of serum B-lymphocyte stimulator in Hodgkin's lymphoma. Haematologica 2007;92:269-70.
20. Rautert R, Schinköthe T, Franklin J, Weihrauch M, Boll B, Pogge E, Bredenfeld H, Engert A, Diehl V, Re D. Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma. Leuk Lymphoma 2008;49:2091-8.
21. Koenecke C, Ukena SN, Ganser A, Franzke A. Regulatory T cells as therapeutic target in Hodgkin's lymphoma. Expert Opin Ther Targets 2008;12:769-82.
22. Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, Vickers MA. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004;103:1755-62.
23. Alvaro T, Lejeune M, Salvadó MT, Bosch R, García JF, Jaén J, Banham AH, Roncador G, Montalbán C, Piris MA. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005;11: 1467-73.
24. Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008;93:193-200.
25. Goetz CA, Harmon IR, O'Neil JJ, Burchill MA, Farrar MA. STAT5 activation underlies IL7 receptor-dependent B cell development. J Immunol 2004;172:4770-78.
26. Lee SK, Surh CD. Role of interleukin-7 in bone and T-cell homeostasis. Immunol Rev 2005;208:169-80.
27. Mazzucchelli R, Durum SK. Interleukin-7 receptor expression: intelligent design. Nat Rev Immunol 2007;7:144-54.
28. Brown VI, Hulitt J, Fish J, Sheen C, Bruno M, Xu Q, Carroll M, Fang J, Teachey D, Grupp SA. Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha signaling. Cancer Res 2007;67:9963-70.
29. Touw I, Pouwels K, van Agthoven T, van Gurp R, Budel L, Hoogerbrugge H, Delwel R, Goodwin R, Namen A, Löwenberg B. Interleukin-7 is a growth factor of precursor B and T acute lymphoblastic leukemia. Blood 1990;75:2097-101.
30. Yamanaka K, Clark R, Rich B, Dowgiert R, Hirahara K, Hurwitz D, Shibata M, Mirchandani N, Jones DA, Goddard DS, Eapen S, Mizutani H, et al. Skin-derived interleukin-7 contributes to the proliferation of lymphocytes in cutaneous T-cell lymphoma. Blood 2006;107:2440-5.
31. Takakuwa T, Nomura S, Matsuzuka F, Inoue H, Aozasa K. Expression of interleukin-7 and its receptor in thyroid lymphoma. Lab Invest 2000;80:1483-90.
32. Rich BE, Campos-Torres J, Tepper RI, Moreadith RW, Leder P. Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice. J Exp Med 1993;177:305-16.
33. Fisher AG, Burdet C, Bunce C, Merkenschlager M, Ceredig R. Lymphoproliferative disorders in IL-7 transgenic mice: expansion of immature B cells which retain macrophage potential. Int Immunol 1995;7:415-23.
34. McBride WH, Thacker JD, Comora S, Economou JS, Kelley D, Hogge D, Dubinett SM, Dougherty GJ. Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity. Cancer Res 1992;52:3931-7.
35. Foss HD, Hummel M, Gottstein S, Ziemann K, Falini B, Herbst H, Stein H. Frequent expression of IL-7 gene transcripts in tumor cells of classical Hodgkin's disease. Am J Pathol 1995;146:33-9.
36. Trümper L, Jung W, Dahl G, Diehl V, Gause A, Pfreundschuh M. Interleukin-7, interleukin-8, soluble TNF receptor, and p53 protein levels are elevated in the serum of patients with Hodgkin's disease. Ann Oncol 1994;5:93-6.
37. DeCoteau JF, Reis MD, Griesser H, Lorenzana A, al-Hashmi I, Hawley RG, Naumov A, White CA, Pinkerton PH. SBH-1, a novel Reed-Sternberg-like cell line capable of inducing tumors in SCID mice: immunophenotypic, cytogenetic, and cytokine expression profiles. Blood 1995;85:2829-38.
38. Drexler HG. Recent results on the biology of Hodgkin and Reed Sternberg cells. II. Continuous cell lines. Leuk Lymphoma 1993;9: 1-25.
39. Wolf J, Kapp U, Bohlen H, Kornacker M, Schoch C, Stahl B, Mucke S, von Kalle C, Fonatsch C, Schaefer HE, Hansmann ML, Diehl V. Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give raise to permanently growing Hodgkin-Reed Sternberg cells. Blood 1996;87:3418-28.
40. Aldinucci D, Poletto D, Nanni P, Degan M, Gloghini A, Di Francia R, Russo S, Carbone A, Pinto A, Gattei V. Hodgkin and Reed-Sternberg cells express functional c-kit receptors and interact with primary fibroblasts from Hodgkin's disease-involved lymph nodes through soluble and membrane-bound stem cell factor. Br J Haematol 2002;118: 1055-64.
41. Aldinucci D, Poletto D, Gloghini A, Nanni P, Degan M, Perin T, Ceolin P, Rossi FM, Gattei V, Carbone A, Pinto A. Expression of functional interleukin-3 receptors on. Hodgkin and Reed-Sternberg cells. Am J Pathol 2002;160:585-96.
42. Levina V, Su Y, Nolen B, Liu X, Gordin Y, Lee M, Lokshin A, Gorelik E. Chemotherapeutic drugs and human tumor cells cytokine network. Int J Cancer 2008;123:2031-40.
43. Allavena P, Garlanda C, Borrello MG, Sica A, Mantovani A. Pathways connecting inflammation and cancer. Curr Opin Genet Dev 2008;18:3-10.
44. Iwata M, Graf L, Awaya N, Torok-Storb B. Functional interleukin-7 receptors (IL-7Rs) are expressed by marrow stromal cells: binding of IL-7 increases levels of IL-6 mRNA and secreted protein. Blood 2002;100:1318-25.
45. Niitsu N, Okamato M, Nakamine H, Yoshino T, Tamaru J, Nakamura S, Higashihara M, Hirano M. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. Eur J Haematol 2002;68:91-100.
46. Kube D, Holtick U, Vockerodt M, Ahmadi T, Haier B, Behrmann I, Heinrich PC, Diehl V, Tesch H. STAT3 is constitutively activated in Hodgkin cell lines. Blood 2001;98:762-70.
47. Gause A, Scholz R, Klein S, Jung W, Diehl V, Tesch H, Hasenclever D, Pfreundschuh M. Increased levels of circulating interleukin-6 in patients with Hodgkin's disease. Hematol Oncol 1991;9: 307-13.
48. Casasnovas RO, Mounier N, Brice P, Divine M, Morschhauser F, Gabarre J, Blay JY, Voillat L, Lederlin P, Stamatoullas A, Bienvenu J, Guiguet M, et al.; Groupe d'Etude des Lymphomes de l'Adulte. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical. Hodgkin's lymphoma: a study from the. Groupe d'Etude des. Lymphomes de l'Adulte. J Clin Oncol 2007; 25:1732-40.
49. Tesch H, Jücker M, Klein S, Abts H, Günther A, Krueger GR, Diehl V. Hodgkin and Reed-Sternberg cells express interleukin 6 and interleukin 6 receptors. Leuk Lymphoma 1992;7:297-303.
50. Reynolds GM, Billingham LJ, Gray LJ, Flavell JR, Najafipour S, Crocker J, Nelson P, Young LS, Murray PG. Interleukin 6 expression by Hodgkin/Reed- Sternberg cells is associated with the presence of 'B' symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease. Br J Haematol 2002;118:195-201.
51. Palmer MJ, Mahajan VS, Trajman LC, Irvine DJ, Lauffenburger DA, Chen J. Interleukin-7 receptor signaling network: an integrated systems perspective. Cell Mol Immunol 2008;5:79-89.
52. Mazzucchelli R, Hixon JA, Spolski R, Chen X, Li WQ, Hall VL, Willette-Brown J, Hurwitz AA, Leonard WJ, Durum SK. Development of regulatory T cells requires IL-7R{alpha} stimulation by IL-7 or TSLP. Blood 2008;112:3283-92.
53. Bayer AL, Lee JY, de la Barrera A, Surh CD, Malek TR. A function for IL-7R for CD4+CD25+Foxp3+ T regulatory cells. J Immunol 2008;181:225-34.
54. Tang Q, Bluestone JA. The Foxp31 regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 2008;9:239-44.
55. Raimondi G, Turner MS, Thomson AW, Morel PA. Naturally occurring regulatory T cells: recent insights in health and disease. Crit Rev Immunol 2007;27:61-95.
56. Koenecke C, Ukena SN, Ganser A, Franzke A. Regulatory T cells as therapeutic target in Hodgkin's lymphoma. Expert Opin Ther Targets 2008;12:769-82.
57. Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T, Nakajima A, Hirohashi S. FOXP31 regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007;13:902-11.
58. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
59. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006;24:5373-80.
60. Tanijiri T, Shimizu T, Uehira K, Yokoi T, Amuro H, Sugimoto H, Torii Y, Tajima K, Ito T, Amakawa R, Fukuhara S. Hodgkin's reed-sternberg cell line (KM-H2) promotes a bidirectional differentiation of CD4+CD25+Foxp3+ T cells and CD4+ cytotoxic T lymphocytes from CD4+ naive T cells. J Leukoc Biol 2007; 82:576-84.
61. Ishida T, Ishii T, Inagaki A, Yano H, Komatsu H, Iida S, Inagaki H, Ueda R. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 2006;66:5716-22.
62. Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009;9:15-27.
63. Buglio D, Georgakis GV, Hanabuchi S, Arima K, Khaskhely NM, Liu YJ, Younes A. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 2008;112:1424-33.
64. de Jong D, Enblad G. Inflammatory cells and immune microenvironment in malignant lymphoma. J Int Med 2008;264:528-36.
65. Mittal S, Marshall NA, Duncan L, Culligan DJ, Barker RN, Vickers MA. Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma. Blood 2008;111:5359-70.
66. Ke X, Wang J, Li L, Chen IH, Wang H, Yang XF. Roles of CD4+CD25(high) FOXP3+ Tregs in lymphomas and tumors are complex. Front Biosci 2008;13:3986-4001.